Sunitinib in pancreatic neuroendocrine tumors. - Wikidata - awgldk - TriplyDB

Sunitinib in pancreatic neuroendocrine tumors.

Sunitinib in pancreatic neuroendocrine tumors.

http://www.wikidata.org/entity/Q38015764

about

Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms Magnetic resonance imaging identifies early effects of sunitinib treatment in human melanoma xenografts.Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.Sunitinib malate (SU-11248) reduces tumour burden and lung metastasis in an intratibial human xenograft osteosarcoma mouse model.The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events.Isoangustone A, a novel licorice compound, inhibits cell proliferation by targeting PI3K, MKK4, and MKK7 in human melanoma The Effect of Sunitinib Treatment in Human Melanoma Xenografts: Associations with Angiogenic Profiles Sunitinib malate for the treatment of pancreas malignancies--where does it fit?Algorithmic approach to neuroendocrine tumors in targeted biopsies: Practical applications of immunohistochemical markers.MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer.

P2860

Q22305863-59A8B68C-7AA0-4D04-8E09-FFDC28E9B358 Q26862544-8AB7E31F-0D3D-47C5-952B-2E10312DF89F Q34249349-34535F68-752A-43DD-AC14-A57B585B31B9 Q35738251-C3CF6331-EA60-4CFE-A846-EB44ECAA7920 Q35993110-A09B9BC4-F364-4C54-A08C-34809FD8D8BF Q37117596-51B3A518-A4B4-4A7E-A896-B2E13736E7F0 Q37375027-5D3EAB51-BCE5-4C21-931C-50D60DCBABD6 Q37627013-6C46621B-978E-416B-BAF6-A1E0B27CB8BE Q38086310-0F564A88-28DF-426D-898F-3DD99492CE49 Q38928817-1C639814-6690-46FF-9BD0-5C6F19FE67CB Q38971815-8A93F9E1-77CF-4708-AB45-35805BDF4A70

P2860

Sunitinib in pancreatic neuroendocrine tumors.

http://www.wikidata.org/entity/Q38015764

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Sunitinib in pancreatic neuroendocrine tumors.

@en

type

label

Sunitinib in pancreatic neuroendocrine tumors.

@en

prefLabel

Sunitinib in pancreatic neuroendocrine tumors.

@en

P1433

Q38015764-97554DB1-DECE-4334-A357-7F7DA57F1DE3

P1476

Q38015764-65D797E7-9570-4A85-9B75-8AEBC990635A

P2093

Q38015764-10BFF6EE-6A3B-4F82-858D-D460E7CA5094

Q38015764-86592CA8-AB4E-411F-A04A-6D4194FE0120

Q38015764-9D82B336-AF05-4E01-AAC3-CC38A1964CF2

Q38015764-D3A65F97-D554-4DDD-8C19-E43B665B5835

Q38015764-DB2DDC9F-632E-40B4-8736-08E68C6F124D

P2860

Q38015764-064CF789-0DF3-48D6-A938-D962D2A2F1CE

Q38015764-0B81E2F2-D11C-4E85-AA37-327FF804F642

Q38015764-1124A882-0DDD-430A-BF2A-C31386EFA1E6

Q38015764-13AF01A1-84A2-4E5A-8771-B765FF828CAF

Q38015764-16FD34A7-450F-4C0E-AA1C-69A9405DD10C

Q38015764-18B15A05-F6FC-4E3D-89BD-CB203667D4AF

Q38015764-20B972AE-073F-4665-9DF8-87B966CEF1B0

Q38015764-267B2893-3B27-4619-9C3F-DA0470979F6F

Q38015764-2689D1B4-FB59-45FD-8B44-64D7AC5A7C51

Q38015764-2A0B28B5-4C13-4D57-B433-D26B1C492EB3

P2888

Q38015764-87E6AE86-FCAF-476E-9FF0-ACDD0C60F91F

P304

Q38015764-6BBBD304-3BF5-48D1-825B-3035F1D43690

P31

Q38015764-24617B52-658B-4154-8CB8-6A5F4F3D8C91

P356

Q38015764-405430F6-3784-4DC5-9B2B-91FD2D6E5901

P433

Q38015764-CC128B14-92E4-4818-B9EE-B852EA439BCB

P478

Q38015764-F22EC06C-A8E2-4D8D-93F6-F7DAA92D0F03

P50

Q38015764-AF18A33B-2258-4372-88A3-411FC1A626B3

Q38015764-FA0E6596-2A93-40DE-BA85-B58FDA6A2A1F

P577

Q38015764-CAB68856-AFB2-42AF-BAB5-2A986C78C54C

P6179

Q38015764-90FC7102-69C1-4A78-A7F7-BF45B87B2754

P698

Q38015764-98B24831-70D0-4718-876E-ABF65F2F69B3

P356

S11523-012-0220-2

P1433

Targeted oncology

P1476

Sunitinib in pancreatic neuroendocrine tumors

@en

P2093

Chantal Dreyer

http://www.w3.org/2001/XMLSchema#string

Christian Maatescu

http://www.w3.org/2001/XMLSchema#string

Eric Raymond

http://www.w3.org/2001/XMLSchema#string

Olivia Hentic

http://www.w3.org/2001/XMLSchema#string

Philippe Ruszniewski

http://www.w3.org/2001/XMLSchema#string

P2860

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis.

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Everolimus for advanced pancreatic neuroendocrine tumors.

Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis

P2888

s11523-012-0220-2

P304

117-125

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-012-0220-2

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Sandrine Faivre

P577

2012-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1051641701

http://www.w3.org/2001/XMLSchema#string

P698

22661319

http://www.w3.org/2001/XMLSchema#string